Elranatamab in Heavily Pretreated Triple-class Refractory Multiple Myeloma: A Single-center Experience

Aim: This study aimed to assess the real-world performance of elranatamab in terms of its effectiveness, safety, and tolerability among patients diagnosed with triple-class refractory-multiple myeloma (TCR-MM) who have undergone extensive prior treatment.Methods: A retrospective review was conducted at a single medical center, involving 12 TCR-MM patients who received elranatamab.Data were analyzed on demographics, cytogenetics, disease burden, prior therapies, infectious complications, and survival outcomes.Responses were assessed according to International Myeloma Working Group criteria, and adverse events were graded per common terminology criteria for adverse events version 5.0.Results: The overall response rate was 83.3%, with a median progression-free survival of 8.0 months and a median overall survival of 11.0 months.Common adverse events included grade 3 infections (75%) and cytokine release syndrome (CRS), which occurred in 41.7% of the participants, with only grade 1-2 CRS observed.No immune effector cell-associated neurotoxicity syndrome was reported.Conclusion: Elranatamab demonstrated promising clinical efficacy and an acceptable safety profile in a heavily pretreated TCR-MM population.The elevated risk of infections necessitates close clinical surveillance.